ReviewMedical mycology2019
The human lung and Aspergillus: You are what you breathe in?
Review in Medical mycology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 86 citations in OpenAlex.
- The role of the respiratory microbiome in acute and chronic respiratory diseases.Nature reviews. Microbiology · 2026Review
- Climate change-driven geographical shifts iniScience · 2026Article
- Urinary Fungal Microbiome and Associations With Overactive Bladder, Antibiotics and Therapy Response.Neurourology and urodynamics · 2026Article
- Epithelial remodeling and microbial dysbiosis in the lower respiratory tract of vitamin A-deficient mouse lungs.Scientific reports · 2026Article
- Proteomic characterization ofVirulence · 2025Article
- Homeostasis of Gut Microbiota Protects against Susceptibility to Fungal Pneumonia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Dancing with the Dust Devil: Examining the Lung Mycobiome of Sonoran Desert Wild Mammals and the Effect ofPathogens (Basel, Switzerland) · 2025Article
- Proposed Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Patients with Autoimmune Inflammatory Rheumatic Diseases: A Proof-of-Concept Study.Journal of fungi (Basel, Switzerland) · 2025Article
- Review
- Phylogenetic and ecological drivers of the avian lung mycobiome and its potentially pathogenic component.Communications biology · 2025Article
- Invasive pulmonary aspergillosis evaluation in hematology patients: Three years results of tertiary hospital.Biomolecules & biomedicine · 2025Article
- Genetic sequencing of the airborne fungal spectrum and air quality at a public hospital in Mexico City.PLOS global public health · 2025Article
- Microbial indoor air pollution in Delhi Metropolitan City is attributable to severe respiratory and general health effects among residents.Frontiers in public health · 2025Article
- A mass spectrometry-based strategy for investigating volatile molecular interactions in microbial consortia: unveiling aFrontiers in microbiology · 2024Article
- The airway mycobiome and interactions with immunity in health and chronic lung disease.Oxford open immunology · 2024Review
- Effect of yeast probioticCurrent medical mycology · 2023Article
- Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization.Pathogens (Basel, Switzerland) · 2023Article
- The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus onLife (Basel, Switzerland) · 2023Review
- Comparison of Multi-locus Genotypes Detected inJournal of fungi (Basel, Switzerland) · 2023Article
- Fungal-Bacterial Interactions in the Human Gut of Healthy Individuals.Journal of fungi (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diversity of fungal species comprising the lung mycobiome is a reflection of exposure to environmental and endogenous filamentous fungi and yeasts. Most lung mycobiome studies have been culture-based. A few have utilized next generation sequencing (NGS). Despite the low number of published NGS studies, several themes emerge from the literature: (1) moulds and yeasts are present in the human respiratory tract, even during health; (2) the fungi present in the respiratory tract are highly variable between individuals; and (3) many diseases are accompanied by decreased diversity of fungi in the lungs. Even in patients with the same disease, different patients have been shown to harbor distinct fungal communities. Those fungal species present in any one individual may represent a patient's unique environmental exposure(s), either to species restricted to the indoor environment, for example, Penicillium, or species found in the outdoor environment such as Aspergillus, wood and vegetation colonizing fungi and plant pathogens. In addition to causing clinical fungal infections, the lung mycobiome may have inflammatory effects that can cause or worsen lung disease. Most respiratory diseases that have been studied, have been associated with decreases in fungal diversity. However, none of these diversity studies distinguish between accidental, transient fungal colonizers and true residents of the respiratory tract. Where does Aspergillus feature in the mycobiomes of the respiratory tract? Do these mycobiomes reflect the diversity of fungi in outdoor and internal environments? These intriguing questions are explored here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.